Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 352

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 352
---
ira exclusive

221

access to Kineta Chronic Pain’s information and personnel for due diligence regarding a potential transaction involving the acquisition and/or licensure of the worldwide patents, patent
rights, patent applications, product and development program assets, technical and business information, and other rights and assets associated with and derived from KCP506 and its development program. The exclusivity period lasts until the earlier
of the execution of a definitive agreement or 11:59 p.m. Eastern Time on January 31, 2025, with a possible 15-day extension. During this period, Kineta agrees not to engaged in discussions or negotiations
with third parties regarding competing transactions and must notify Pacira of any unsolicited offers. In return, Pacira paid Kineta Chronic Pain a non-refundable and
non-creditable exclusivity payment of $50,000.

On January 29, 2025, Kineta and GigaGen
entered into the GigaGen Agreement.

On February 4, 2025, Kineta Chronic Pain and Pacira entered into the Pacira Asset Purchase Agreement.

On February 4, 2025, Kineta and HCRX entered into the HCRX Asset Purchase Agreement.

In April 2025, TuHURA and Kineta began discussing one or more potential amendments to the Merger Agreement to help facilitate the completion
of the Mergers, particularly in light of the financing needs associated with the potential transaction. The original Merger Agreement entered into on December 11, 2024 (the “Original Merger Agreement”) provided that the amount of the
Concurrent Investment would need to be a minimum of $35.0 million in net proceeds, that the Closing Adjusted Cash Consideration would be calculated with an initial base amount of $15.0 million, that the Initial Share Consideration would be $15.0
million, that the Kineta Delayed Share Consideration would be an amount equal to $5.0 million, and that the Estimated Net Working Capital Deficit would not exceed $12.0 million. In March and April 2025, the parties discussed the implications of
changes in the capital markets since the date of the Original Merger Agreement that have affected TuHURA’s ability to enter into a definitive agreement for a Concurrent Investment. They also discussed the ongoing costs and expenses of Kineta
continuing to operate as a publicly traded company, the cash needs associated with Kineta’s ongoing KVA12123 trial and development program,